Please assess the completion status of the following clinical trial:

Trial Title: A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Tissue from an archived or fresh tumor sample~* A peripheral blood buffy coat sample is required for CLL/SLL.~* Patient has mantle cell lymphoma (MCL), follicular lymphoma (FL), or chronic lymphocytic leukemia (CLL)/SLL or diffuse large B cell lymphoma~* Patient \> or = 18 years old~* Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2. Patients with DLBCL will have ECOG \< or = 1~* Adequate white blood cells and hemoglobin~* Good kidney and liver function~* Fasting glucose \< 160 mg/dL~* No other malignancy~* Use of adequate birth control~Exclusion criteria:~* Treatment with cytotoxic chemotherapy, biologic agents, investigational therapies within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks of study enrollment~* Treatment with a small-molecule kinase inhibitor within 2 weeks, or 5 half lives of the drug or its active metabolites (whichever is longer) of study enrollment~* Prior treatment with a PI3K, mTOR, or Akt inhibitor. Prior treatment of MCL with temsirolimus is permitted in patients enrolled from countries where it is licensed for this indication.~* Radiation therapy within 2 weeks of enrollment~* Autologous stem cell transplantation within 16 weeks of enrollment~* Prior allogeneic transplantation except for patients with R/R DLBCL who meet inclusion criteria~* Central nervous system (CNS) or leptomeningeal involvement. Patients with DLBCL may have active CNS or leptomeningeal involvement.~* Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (anti-HCV) serology~* Primary CNS lymphoma~* Primary mediastinal B-lymphoma~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mantle cell (Type: EXPERIMENTAL): 50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
- follicular lymphoma (Type: EXPERIMENTAL): 50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
- CLL/SLL (Type: EXPERIMENTAL): 50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
- Diffuse large B cell lymphoma (Type: EXPERIMENTAL): 50 mg twice daily:no eating for 2 hours prior and 1 hour after dose

Based on this trial design, predict the completion outcome and termination type (if applicable).